vtvt-8k_20160512.htm

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (date of earliest event reported):  May 12, 2016

vTv Therapeutics Inc.
(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction

of incorporation)

001-37524

(Commission File No.)

47-3916571
(IRS Employer
Identification No.)

 

4170 Mendenhall Oaks Pkwy

High Point, NC 27265

(Address of principal executive offices)

 

(336) 841-0300

(Registrant’s telephone number, including area code)  

NOT APPLICABLE

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a‑12)

 

o

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


 

Item 5.07 Submission of Matters to a Vote of Security Holders 

On May 12, 2016, vTv Therapeutics Inc. (the “Company”) held its 2016 Annual Meeting of Stockholders (the “Annual Meeting”).  The matters voted on at the Annual Meeting and the votes cast with respect to each such matter are set forth below:

 

(1)

The Company’s stockholders elected the nominees listed below to the Company’s Board of Directors, each to serve for a term to expire at the Company’s 2017 annual meeting of stockholders or until their successors are duly elected and qualified based on the following results of the voting:

Director Nominee

  

For

 

  

Against

 

  

Withheld

 

  

Broker Non-Votes

 

 

Jeffrey B. Kindler

  

 

27,517,869

  

  

 

0

  

  

 

1,206,136

  

  

 

2,933,521

 

  

Steven M. Cohen

  

 

26,512,992

  

  

 

0

  

  

 

2,211,013

  

  

 

2,933,521

 

  

John A. Fry

  

 

28,706,769

  

  

 

0

  

  

 

17,236

  

  

 

2,933,521

 

  

Paul M. Meister

 

 

27,517,869

 

 

 

0

 

 

 

1,206,136

 

 

 

2,933,521

 

 

Craig C. Parker

 

 

28,465,193

 

 

 

0

 

 

 

258,812

 

 

 

2,933,521

 

 

Paul G. Savas

 

 

27,514,898

 

 

 

0

 

 

 

1,209,107

 

 

 

2,933,521

 

 

Noel J. Spiegel

 

 

28,696,883

 

 

 

0

 

 

 

27,122

 

 

 

2,933,521

 

 

 

 

(2)

The appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016 was ratified based on the following results of the voting:

For

 

 

Against

 

 

Abstain

 

 

31,646,599

  

 

 

9,728

  

 

 

1,199

  

 


2


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

VTV THERAPEUTICS INC.

 

By:

/s/ Rudy C. Howard

Name:

Rudy C. Howard

Title:

Chief Financial Officer

 

Dated: May 16, 2016

3